On 28 July 2026, surgeons at Wuhan Union Hospital, part of Tongji Medical College at Huazhong University of Science and Technology, removed a 45-gram artificial heart from the chest of an 8-year-old boy and replaced it with a donor organ. The pump had been running for 485 days.
The hospital announced the case on 15 October, the day the boy left intensive care for a general ward. It described the operation as the world's first successful bridge to transplant after long-term biventricular support with a fully magnetically levitated pediatric device, and said 485 days set a record for the longest support of its kind in a child. We found no independent registry entry or peer-reviewed report confirming either claim.
The case
The boy, identified in Chinese reports by the pseudonym Junjun, was diagnosed with dilated cardiomyopathy in 2024. He also had severe regurgitation of the mitral and tricuspid valves. By March 2025 his heart function had deteriorated into cardiogenic shock; his left ventricular ejection fraction was 27%, and he was placed on ECMO on 19 March.
The assist device went in on 30 March 2025, when he was 7. The operation took five hours. He was breathing without support the next day and moved to an isolation ward on the fifth day. He went home in July 2025.
He has type O blood, which made donor matching harder. A compatible heart became available on 28 July 2026. The transplant was performed the same day through China's national organ allocation system, with 155 minutes of cardiopulmonary bypass. He left intensive care on 15 October, about eleven weeks later.
The 485-day figure checks out against the dates: 30 March 2025 to 28 July 2026 is 485 days.
| Date | Event |
|---|---|
| 2024 | Diagnosed with dilated cardiomyopathy |
| 19 March 2025 | Cardiogenic shock; placed on ECMO |
| 30 March 2025 | Biventricular assist device implanted |
| July 2025 | Discharged home |
| 28 July 2026 | Heart transplant |
| 15 October 2026 | Transferred out of intensive care |
The pump
The device weighs 45 grams and measures 2.9 cm across. It is a third-generation fully magnetically levitated biventricular assist device, built for children, and the hospital describes it as the smallest and lightest artificial heart of its kind. It can support children weighing 8 kg or more, according to the reports.
Xinhua's April 2025 report on the implantation said the device was developed with Shenzhen Core Medical Technology Co., Ltd. The October 2026 reports do not name the company, describing it only as independently developed. The hospital has not published the model designation, and Shenzhen Core Medical has several pediatric and biventricular products in development. Public reports do not say which one was used.
Why the duration matters
Most children with end-stage heart failure either get a transplant quickly or die waiting. The hospital's figures, repeated across the Chinese coverage, give the scale: about 40,000 children are admitted with heart failure in China each year, 7% to 10% of them need urgent transplantation, and 148 pediatric heart transplants were performed nationwide in 2024. The hospital puts mortality among children with acute heart failure waiting for a donor at 40%.
A pump that runs for more than a year without replacement changes the options for a child with no other route to transplant. It does not create donor organs. It buys time.
Dong Nianguo, director of cardiovascular surgery at the hospital, led both operations. The team also included Xia Jiahong, Su Wei, Zhou Cheng, Wang Guohua and Xia Tian.
What the record does not tell you
Three formulations appear in the Chinese coverage. The broadest says the case is the world's first successful bridge to transplant after long-term biventricular support with a fully magnetically levitated pediatric device. A narrower one says it is the longest pediatric biventricular support on record. Changjiang Daily adds that the boy was the youngest patient to receive this particular device's biventricular implant. The three are compatible. They are not identical, and none has been checked against an international registry.
No follow-up data, device-related adverse events, or peer-reviewed case report have been published. Thrombosis, infection and pump failure are the recognized risks of long-term mechanical support; none of the coverage quantifies them for this patient.
One nearby case is easy to confuse with this one. In September 2025, Nanjing Children's Hospital reported a 5-year-old weighing 13 kg who received a different biventricular device, with pumps of about 70 grams each, and described that operation as a record for the youngest and lightest patient. Different hospital, different device, different record. The two should not be merged.
Two cases, two records
China has been developing pediatric ventricular assist devices for several years. Wuhan's case is the first to report a bridge of this length. A second center reported a separate pediatric implant later that year, which suggests the technology is moving beyond one team, though two cases do not make a trend.
For families outside China, the case is informative rather than actionable. Pediatric heart transplantation in China runs inside the national organ allocation system, and foreign patients fall under separate approval rules that this article does not address.
What the case shows, narrowly, is that a fully magnetically levitated pump small enough for a young child can serve as a bridge for more than a year, in at least one center, without being replaced. The hospital has not said whether it plans to publish follow-up data. Until it does, this stands as a single report from a single center, and the record stays a claim rather than a measured fact.
Editorial note: all clinical details come from Chinese-language reports published by Hubei Daily, Changjiang Daily, Hubei Broadcasting and Television, and Guangming Online between 15 and 17 October 2026, and from Xinhua's April 2025 report on the original implantation. The "world's first" and "longest" descriptions are attributed to the hospital and have not been independently verified. The device manufacturer is named only where a primary report names it. Patient details are limited to what the hospital and its media partners have already made public.
